Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	$ 4,117,783	$ 3,706,918	$ 12,662,290	$ 10,590,237
Cost of revenues	4,012,369	2,975,935	11,515,168	9,603,048
Research and development	8,469,623	4,486,389	19,024,728	11,619,843
Selling, general, and administrative	7,894,291	5,557,425	24,310,324	15,681,731
Total operating costs and expenses	20,376,283	13,019,749	54,850,220	36,904,622
Operating loss	(16,258,500)	(9,312,831)	(42,187,930)	(26,314,385)
Other income (expense):
Other income (expense), net	(687,280)	179,605	(1,062,568)	248,161
Interest expense	(183,477)	(98,618)	(383,539)	(208,023)
Nonoperating Income (Expense), Total	(870,757)	80,987	(1,446,107)	40,138
Loss before provision for income taxes and noncontrolling interests	(17,129,257)	(9,231,844)	(43,634,037)	(26,274,247)
Provision for income taxes	47,387	44,757	142,183	492,325
Net loss	(17,176,644)	(9,276,601)	(43,776,220)	(26,766,572)
Less - loss attributable to noncontrolling interests	(202,375)	(205,844)	(514,877)	(319,880)
Net loss attributable to NeoStem, Inc. common stockholders	$ (16,974,269)	$ (9,070,757)	$ (43,261,343)	$ (26,446,692)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$ (0.48)	$ (0.45)	$ (1.37)	$ (1.43)
Weighted average common shares outstanding	35,053,218	20,203,934	31,663,221	18,482,413